Meeting
2020 ASCO Virtual Scientific Program
A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part.
Authors
Mitsuya Ishikawa
Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
Mitsuya Ishikawa , Ryo Kitagawa , Taro Shibata , Hideki Tokunaga , Takashi Iwata , Shin Nishio , Toshio Takada , Masahiko Mori , Koji Horie , Wataru Kudaka , Masahiro Kagabu , Michihiro Tanikawa , Hiroaki Kobayashi , Nobuo Yaegashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
jRCTs031180007
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6027)
DOI
10.1200/JCO.2020.38.15_suppl.6027
Abstract #
6027
Poster Bd #
198
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
First Author: Fabian Trillsch
Poster
2018 ASCO Annual Meeting
A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311).
First Author: Ryo Kitagawa
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2019 ASCO Annual Meeting
A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma (NCT02023710).
First Author: Xieqiao Yan